Difference between revisions of "Team:SDU-Denmark/Tour12"

Line 8: Line 8:
 
<p> Despite our tireless efforts we could not have done this on our own. Therefore we would like to express our gratitude. </p>   
 
<p> Despite our tireless efforts we could not have done this on our own. Therefore we would like to express our gratitude. </p>   
 
<h2> Sponsors </h2>
 
<h2> Sponsors </h2>
<img class="popupImg alignRight" src="https://static.igem.org/mediawiki/2015/2/24/SDU2015_logobl%C3%A5.png" width="90px"> </img>
+
<img class="popupImg alignRight" src="https://static.igem.org/mediawiki/2015/2/24/SDU2015_logobl%C3%A5.png" width="100px"> </img>
 
<ul>
 
<ul>
 
<li><p> <a href="http://www.sdu.dk/en/" target="_blank">University of Southern Denmark</a> </p> </li>
 
<li><p> <a href="http://www.sdu.dk/en/" target="_blank">University of Southern Denmark</a> </p> </li>

Revision as of 22:34, 10 September 2015

Attributions

Despite our tireless efforts we could not have done this on our own. Therefore we would like to express our gratitude.

Sponsors

Laboratory support

  • Our instructors Postdoc and Ph. D. Mikkel Girke Jørgensen, Academic Assistant Tina Kronborg, Ph. D. student Thøger Jensen Krogh and Stud.cand.scient Patrick Rosendahl Andreassen
  • Medical Laboratory Technician Simon Rose who

General support

  • DTU – for arranging the anually bio brick workshop
  • Vilnius iGEM team – for hosting our visit for three days
  • The SDU iGEM team 2013
  • Uppsala iGEM team - Nordic Meetup
  • Associate professor, MD Søren Thue Lillevang. Department of Clinical Immunology, Odense University Hospital. He attributed to the discussion about medical aspects
  • Associate Professor Jan Nehlin, Department of Clinical Immunology Odense University Hospital.
  • Nancy Rasmussen - for helping us proof reading our wiki.

Technical support

Litterature support

Antibody issue

  • Lubert Stryer JMB, John L. Tymoczko. The Immune System. Biochemistry. 7 ed: W. H. Freeman and Company; 2012.
  • Cowan MK. Host Defenses II - Specific Immunity and Immunization. Microbiology - A Systems Approach. 3 ed: McGraw-Hill; 2012.
  • Chippaux JP, Goyffon M. Venoms, antivenoms and immunotherapy. Toxicon. 1998;36(6):823-46.
  • Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73-8.
  • Siddiqui MZ. Monoclonal antibodies as diagnostics; an appraisal. Indian J Pharm Sci. 2010;72(1):12-7.
  • Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14-30.
  • Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-87.
  • BioPharma P. What Are Humanized Monoclonal Antibodies 2015 [cited 2015 08/08]. (Link)
  • Payne WJ, Jr., Marshall DL, Shockley RK, Martin WJ. Clinical laboratory applications of monoclonal antibodies. Clin Microbiol Rev. 1988;1(3):313-29.
  • Hnasko RM, Stanker LH. Hybridoma Technology. Methods Mol Biol. 2015;1318:15-28.
  • Stills HF, Jr. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 2005;46(3):280-93.
  • Descartes Rene. Les Méditations métaphysiques’, 1647
  • Bentham Jeremy, Introduction to the Principles of Morals and Legislation, 1789
  • Three RS (Link)
  • Cruelty Free International (Link)
  • Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Demystified …: Monoclonal antibodies. Molecular Pathology. 2000;53(3):111-7.
  • Colas P. The eleven-year switch of peptide aptamers. Journal of biology. 2008;7(1):2.
  • Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature. 1996;380(6574):548-50.
  • Borghouts C, Kunz C, Delis N, Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Molecular cancer research : MCR. 2008;6(2):267-81.
  • Evans D, Johnson S, Laurenson S, Davies AG, Ko Ferrigno P, Wälti C. Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays. Journal of biology. 2008;7(1):3.
  • Li J, Tan S, Chen X, Zhang CY, Zhang Y. Peptide aptamers with biological and therapeutic applications. Current medicinal chemistry. 2011;18(27):4215-22.
  • Swiss Institute of Bioinformatics. 2015. (Link)
  • Key Benefits: Affimers have some simple but essential advantages over antibodies: Avacta Life Sciences; [updated 19-08-2015]. (Link)

P.A.S.T

Results

Practices